Skip to content

Efficacy and safety of Mesenchymal stem cell injection for the treatment of acute myocardial infarction: a single blinding, muticenter randomized control trial.

Efficacy and safety of Mesenchymal stem cell injection for the treatment of acute myocardial infarction: a single blinding, muticenter randomized control trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000080
Enrollment
Unknown
Registered
2008-04-10
Start date
2008-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-elevated acute myocardial infarction (ST-AMI)

Interventions

Group A:Routine therapy as Guideline recommended+ PCI
Group B:Routine therapy as Guideline recommended+ PCI+transplantation of (MSCs)

Sponsors

Navy general hospital of China liberation army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosis is ST-elevated acute myocardial infarction based by WHO standard; 2. Less than 1 month since the onset of ST-AMI; 3. Successfully vessel reconstructed and TIMI>3; 4. Age>18 years old; 5. Patients who sign informed consent form and can finish whole follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients who are complicated with other heart disease, including: Refractory sustained ventricle tachycardia; Severe heart block and not controlled by heart pace maker; Genetic heart disease; Primary heart valve disease; Active myocarditis; Pulmonary heart disease, etc.; 2. Liver or kidney dysfunction (ALT>80U/L, Cr>440mmol/L); 3. Patients with autoimmune disease or any other severe fatality disease; 4. Patients have contradictions of percutaneous coronary intervention; 5. Patients with psychiatric disease.

Design outcomes

Primary

MeasureTime frame
Left ventricle ejective fraction;Change of myocardial metabolis;

Secondary

MeasureTime frame
Mortality;Incidence of cardiovascular event;

Countries

China

Contacts

Public ContactLianru Gao
lianru@yahoo.com.cn+86 0 13381207121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026